Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
116.34
+3.49 (3.09%)
Aug 12, 2026, 12:54 PM EDT - Market open
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $141.53. The average 1-year stock price forecast is 21.66% higher than the current stock price, while the lowest is $105 (-9.74%) and the highest is $160 (+37.53%).
Price Target: $141.53 (+21.66%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $146 | Buy | Reiterates | $146 | +25.50% | Aug 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $136 → $150 | Buy | Reiterates | $136 → $150 | +28.94% | Aug 5, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $141 → $155 | Buy | Reiterates | $141 → $155 | +33.24% | Aug 5, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $143 | Buy | Reiterates | $143 | +22.92% | Aug 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $151 → $154 | Buy | Maintains | $151 → $154 | +32.38% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
313.57M
from 189.76M
Increased by 65.25%
Revenue Next Year
561.11M
from 313.57M
Increased by 78.94%
EPS This Year
-3.07
from -3.11
EPS Next Year
-0.61
from -3.07
EPS and Forward PE are based on non-GAAP adjusted numbers.